drugset
drugset / Trial / NCT05315479

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

NCT05315479 ↗

Phase 4 Terminated 19 enrolled Baudax Bio
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to \<17 years.

Timeline

Start
2022-02-24
Primary completion
2022-07-07
Completion
2022-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 0.6 mg/kg Intravenous

Indications

No indication recorded.